hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

摘要: Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). uptake into tumor cells mainly through human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker gemcitabine efficacy but reports are conflicting, with an important heterogeneity in methods to assess hENT1 expression. A multicenter cohort 471 patients resected PDAC used simultaneously value 2 best described antibodies (10D7G2 and SP120). Three additional mRNA were also tested on 251 302 patients, respectively. expression assessed 54 matched primary tumors metastases samples. The 10D7G2 clone only antibody whose high associated prolonged progression free survival overall who received adjuvant gemcitabine. level benefit. status concordant 83% cases concordance synchronous metastases. has benefit patients. Since it not commercially available, could represent alternative status.